Larimar Therapeutics Inc (LRMR)

Currency in USD
4.795
+0.115(+2.46%)
Real-time Data·
LRMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.5804.840
52 wk Range
1.6106.420
Key Statistics
Prev. Close
4.68
Open
4.59
Day's Range
4.58-4.84
52 wk Range
1.61-6.42
Volume
596.17K
Average Volume (3m)
4.19M
1-Year Change
113.1111%
Book Value / Share
0.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LRMR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.700
Upside
+248.28%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Larimar Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc SWOT Analysis


Nomlabofusp Promise
Larimar's lead drug candidate shows potential to address the root cause of Friedreich's ataxia, positioning the company at the forefront of FA treatment research
Clinical Milestones
Explore Larimar's progress in adult and pediatric trials, with key data releases expected to serve as potential catalysts for stock performance
Regulatory Landscape
Learn about Larimar's strategy for accelerated approval and how potential FDA easements for rare diseases could impact the company's timeline
Market Dynamics
Delve into Larimar's positioning in the evolving FA treatment market, with analyst price targets ranging from $10 to $40 despite recent stock volatility
Read full SWOT analysis

Compare LRMR to Peers and Sector

Metrics to compare
LRMR
Peers
Sector
Relationship
P/E Ratio
−3.0x−6.2x−0.5x
PEG Ratio
0.04−0.200.00
Price/Book
6.3x3.0x2.6x
Price / LTM Sales
-56.9x3.1x
Upside (Analyst Target)
241.9%66.7%55.9%
Fair Value Upside
Unlock−18.2%7.4%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.700
(+248.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
William Blair
Buy---MaintainMar 19, 2026
Guggenheim
Buy26.00+441.67%-MaintainMar 19, 2026
Wedbush
Buy12.00+150.00%11.00MaintainMar 03, 2026
Citi
Buy14.00+191.67%12.00MaintainFeb 24, 2026
Jones Trading
Buy13.00+170.83%7.00MaintainFeb 24, 2026

Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
-0.73 / -0.49
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LRMR Income Statement

People Also Watch

0.393
MOBX
-10.70%
6.640
RLMD
-0.30%
0.3829
ASNS
-4.77%
0.8800
CISS
+2.86%
2.28
ELPW
-2.56%

FAQ

What Is the Larimar Therapeutics Inc (LRMR) Stock Price Today?

The Larimar Therapeutics Inc stock price today is 4.795 USD.

What Stock Exchange Does Larimar Therapeutics Inc Trade On?

Larimar Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Larimar Therapeutics Inc?

The stock symbol for Larimar Therapeutics Inc is "LRMR."

What Is the Larimar Therapeutics Inc Market Cap?

As of today, Larimar Therapeutics Inc market cap is 496.040M USD.

What Is Larimar Therapeutics Inc's Earnings Per Share (TTM)?

The Larimar Therapeutics Inc EPS (TTM) is -2.271.

When Is the Next Larimar Therapeutics Inc Earnings Date?

Larimar Therapeutics Inc will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is LRMR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Larimar Therapeutics Inc Stock Split?

Larimar Therapeutics Inc has split 1 times.

How Many Employees Does Larimar Therapeutics Inc Have?

Larimar Therapeutics Inc has 71 employees.

What is the current trading status of Larimar Therapeutics Inc (LRMR)?

As of Mar 26, 2026, Larimar Therapeutics Inc (LRMR) is trading at a price of 4.795 USD, with a previous close of 4.680 USD. The stock has fluctuated within a day range of 4.580 USD to 4.840 USD, while its 52-week range spans from 1.610 USD to 6.420 USD.

What Is Larimar Therapeutics Inc (LRMR) Price Target According to Analysts?

The average 12-month price target for Larimar Therapeutics Inc is 16.700 USD, with a high estimate of 26 USD and a low estimate of 7 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +248.28% Upside potential.

What Is the LRMR Premarket Price?

LRMR's last pre-market stock price is 4.560 USD. The pre-market share volume is 8,930.000, and the stock has decreased by -0.120, or -2.560%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.